ZYMEWORKS INC. Revenue
ZYMEWORKS INC. (ZYME) reported Revenue of $4.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- ZYMEWORKS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $4.59M, a 90.58% decline year-over-year.
- ZYMEWORKS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $2.41M, a 91.12% decline year-over-year.
- ZYMEWORKS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $2.52M, a 91.90% decline year-over-year.
- ZYMEWORKS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $27.61M, a 72.59% increase year-over-year.
- ZYMEWORKS INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $105.97M, a 38.87% increase from fiscal 2024.
- ZYMEWORKS INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $76.30M, a 0.38% increase from fiscal 2023.
- ZYMEWORKS INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $76.01M, a 81.57% decline from fiscal 2022.
- ZYMEWORKS INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $412.48M, a 1446.03% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.59M 10-Q · filed 2026-08-06 | $7.00M 10-Q · filed 2026-08-06 | $9.51M derived: sum of 3 quarters · filed 2026-08-06 | $37.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.41M 10-Q · filed 2026-05-07 | $4.92M derived: sum of 2 quarters · filed 2026-05-07 | $32.54M derived: sum of 3 quarters · filed 2026-05-07 | $81.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $30.13M derived: sum of 2 quarters · filed 2026-03-02 | $78.86M derived: sum of 3 quarters · filed 2026-08-06 | $105.97M 10-K · filed 2026-03-02 |
| 2025-09-30 | $27.61M 10-Q · filed 2025-11-06 | $76.34M derived: sum of 2 quarters · filed 2026-08-06 | $103.45M 10-Q · filed 2025-11-06 | $134.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $48.73M 10-Q · filed 2026-08-06 | $75.84M 10-Q · filed 2026-08-06 | $106.87M derived: sum of 3 quarters · filed 2026-08-06 | $122.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $27.11M 10-Q · filed 2026-05-07 | $58.14M derived: sum of 2 quarters · filed 2026-05-07 | $74.14M derived: sum of 3 quarters · filed 2026-05-07 | $93.38M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $31.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $47.03M derived: sum of 2 quarters · filed 2026-03-02 | $66.27M derived: sum of 3 quarters · filed 2026-03-02 | $76.30M 10-K · filed 2026-03-02 |
| 2024-09-30 | $16.00M 10-Q · filed 2025-11-06 | $35.24M derived: sum of 2 quarters · filed 2025-11-06 | $45.27M 10-Q · filed 2025-11-06 | $62.20M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $19.24M 10-Q · filed 2025-08-07 | $29.27M 10-Q · filed 2025-08-07 | $46.20M derived: sum of 3 quarters · filed 2026-03-02 | $62.70M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $10.03M 10-Q · filed 2025-05-08 | $26.96M derived: sum of 2 quarters · filed 2026-03-02 | $43.46M derived: sum of 3 quarters · filed 2026-03-02 | $50.46M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $16.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $33.43M derived: sum of 2 quarters · filed 2026-03-02 | $40.43M derived: sum of 3 quarters · filed 2026-03-02 | $76.01M 10-K · filed 2026-03-02 |
| 2023-09-30 | $16.51M 10-Q · filed 2024-10-31 | $23.51M derived: sum of 2 quarters · filed 2024-10-31 | $59.09M 10-Q · filed 2024-10-31 | $461.58M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $7.00M 10-Q · filed 2024-08-01 | $42.58M 10-Q · filed 2024-08-01 | $445.07M derived: sum of 3 quarters · filed 2025-03-05 | $447.70M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $35.58M 10-Q · filed 2024-05-02 | $438.07M derived: sum of 2 quarters · filed 2025-03-05 | $440.70M derived: sum of 3 quarters · filed 2025-03-05 | $446.14M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $402.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $405.12M derived: sum of 2 quarters · filed 2025-03-05 | $410.57M derived: sum of 3 quarters · filed 2025-03-05 | $412.48M 10-K · filed 2025-03-05 |
| 2022-09-30 | $2.63M 10-Q · filed 2023-11-07 | $8.07M derived: sum of 2 quarters · filed 2023-11-07 | $9.99M 10-Q · filed 2023-11-07 | $29.86M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $5.44M 10-Q · filed 2023-08-10 | $7.36M 10-Q · filed 2023-08-10 | $27.23M derived: sum of 3 quarters · filed 2024-03-06 | $31.62M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $1.92M 10-Q · filed 2023-05-08 | $21.79M derived: sum of 2 quarters · filed 2024-03-06 | $26.18M derived: sum of 3 quarters · filed 2024-03-06 | |
| 2021-12-31 | $19.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $24.27M derived: sum of 2 quarters · filed 2024-03-06 | $26.68M 10-K · filed 2024-03-06 | |
| 2021-09-30 | $4.39M 10-Q · filed 2022-11-08 | $6.81M 10-Q · filed 2022-11-08 | ||
| 2020-12-31 | $38.95M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |